Global Achondroplasia Market to Surpass US$ 1,100.97 Million by 2030, Says Coherent Market Insights (CMI) seattle, July 25, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global achondroplasia market is estimated to be valued at US$ 93.82 million in 2022 and is expected to exhibit a...

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose Consistent Safety Profile at High Dose Findings Support 15...

BioMarin Provides Program Update on Vosoritide in Achondroplasia New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocityfor up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at...